Rosuvastatin For Lowering Lipids
S. Adams, S. Sekhon, J. M. Wright
Published 2014 · Medicine
Download PDFAnalyze on Scholarcy
Background Rosuvastatin is one of the most potent statins and is currently widely prescribed. It is therefore important to know the dose-related magnitude of effect of rosuvastatin on blood lipids. Objectives Primary objective To quantify the effects of various doses of rosuvastatin on serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, non-HDL-cholesterol and triglycerides in participants with and without evidence of cardiovascular disease. Secondary objectives To quantify the variability of the effect of various doses of rosuvastatin. To quantify withdrawals due to adverse effects (WDAEs) in the randomized placebo-controlled trials. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 10 of 12, 2014 in The Cochrane Library, MEDLINE (1946 to October week 5 2014), EMBASE (1980 to 2014 week 44), Web of Science Core Collection (1970 to 5 November 2014) and BIOSIS Citation Index (1969 to 31 October 2014). No language restrictions were applied. Selection criteria Randomized controlled and uncontrolled before-and-after trials evaluating the dose response of different fixed doses of rosuvastatin on blood lipids over a duration of three to 12 weeks. Data collection and analysis Two review authors independently assessed eligibility criteria for studies to be included and extracted data. WDAEs information was collected from the placebo-controlled trials. Main results One-hundred and eight trials (18 placebo-controlled and 90 before-and-after) evaluated the dose-related efficacy of rosuvastatin in 19,596 participants. Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method. The quality of evidence for these effects is high. Log dose-response data over doses of 1 to 80 mg, revealed strong linear dose-related effects on blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol. When compared to atorvastatin, rosuvastatin was about three-fold more potent at reducing LDL-cholesterol. There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%. There is a high risk of bias for the trials in this review, which would affect WDAEs, but unlikely to affect the lipid measurements. WDAEs were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials (risk ratio 0.84; 95% confidence interval 0.48 to 1.47). Authors' conclusions The total blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol-lowering effect of rosuvastatin was linearly dependent on dose. Rosuvastatin log dose-response data were linear over the commonly prescribed dose range. Based on an informal comparison with atorvastatin, this represents a three-fold greater potency. This review did not provide a good estimate of the incidence of harms associated with rosuvastatin because of the short duration of the trials and the lack of reporting of adverse effects in 44% of the placebo-controlled trials.
This paper references
Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels
Stefania E. Makariou (2012)
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
D. Schneck (2003)
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
H. Lee (2013)
The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
J. Herd (1998)
Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
L. Ose (1995)
Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure
A. Tekin (2008)
Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype.
A. Dergunov (2003)
Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study.
B. O'Rourke (2004)
Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
M. Yogo (2014)
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain
V. Barrios (2012)
Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention
T. Delea (2005)
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
J. Blasetto (2003)
Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects.
A. Saitta (2000)
Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
H. Eichstaedt (1995)
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
H. Greten (1994)
The Effect of Fluvastatin on Parameters of Bone Remodeling
N. Bjarnason (2001)
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
M. Ai (2008)
Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment
G. Schectman (1996)
Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
H. Milionis (2006)
Non-high-density lipoprotein cholesterol as a risk factor: addressing risk associated with apolipoprotein B-containing lipoproteins
M. Chapman (2004)
Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic Women
G. Baggio (2012)
Chapter 12: Interpreting results and drawing conclusions
H. Schünemann (2011)
Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
A. Gottsäter (1999)
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
J. Benner (2005)
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin.
S. Turban (2001)
A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia
M. Berger (1996)
Vasodilatory Capacity of Forearm Resistance Vessels Is Augmented in Hypercholesterolemic Patients After Treatment with Fluvastatin
H. Schobel (1998)
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.
G. Riegger (1999)
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
A. D. Marais (2008)
Rosuvastatina para tratamiento de la dislipidemia en pacientes infectados con VIH en tratamiento antirretroviral de gran actividad. Experiencia preliminar
E. Bottaro (2008)
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
M. Kostapanos (2008)
Effects of Manidipine Plus Rosuvastatin Versus Olmesartan Plus Rosuvastatin on Markers of Insulin Resistance in Patients With Impaired Fasting Glucose, Hypertension, and Mixed Dyslipidemia
E. Liberopoulos (2013)
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
M. Hirsch (2005)
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
M. Hongo (2008)
Rosuvastatina y metformina reducen la inflamación y el estrés oxidativo en pacientes con hipertensión y dislipemia
A. Gómez-García (2007)
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.
A. Ichihara (2002)
Statin treatment and exercise: Is there an additive anti -inflammatory effect?
P. Coen (2008)
Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure
L. Lullo (2005)
Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULiPS (Turkish Lipid Study)
B. Ilerigelen (2007)
[Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
L. Kłosiewicz-latoszek (2003)
Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion
M. Kostapanos (2007)
Statins for the primary prevention of cardiovascular disease.
F. Taylor (2013)
Chapter 10: Addressing reporting biases
M. Egger (2011)
Lessons from Clinical Trials: LCAS and Other Studies
J. A. Herd (1998)
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
M. Kostapanos (2007)
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
A. Agouridis (2011)
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus
P. Jones (2010)
Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia.
H. Mabuchi (2004)
Baseline Very Low-Density Lipoprotein Cholesterol is Associated with the Magnitude of Triglyceride Lowering on Statins, Fenofibric Acid, or Their Combination in Patients with Mixed Dyslipidemia
A. Sharma (2014)
Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia
Alfredo P Buzzi (1997)
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins
S. Bergheanu (2008)
Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin.
M. Güthlin (1999)
Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population
H. Buzková (2012)
Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.
D. Tousoulis (2010)
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
L. Puccetti (2011)
Atorvastatin for lowering lipids
S. Adams (2015)
High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study.
S. Erbs (2011)
Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.
K. Tan (1999)
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
T. Yamazaki (2013)
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
D. Hunninghake (2004)
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report
P. Valdivielso (2009)
Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1.
Jing-Zhi Guan (2004)
How green is your roof
Mike Garnham (2006)
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
I. Andreou (2010)
An Economic Analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)
D. Smith (2012)
Starting with Rosuvastatin in Primary Hyperlipidemia—
H. Milionis (2005)
Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients
Karl-Ludwig Schulte (1996)
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
A. Stalenhoef (2005)
Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial.
R. Capoulade (2013)
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Vijaya M Musini (2014)
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
E. Leitersdorf (1994)
Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study
D. Jassal (2011)
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
M. Bevilacqua (1997)
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
A. Brown (1998)
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
T. Jacobson (1994)
The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
H. Bays (2010)
[The hypolipidemic effect of and tolerance for Lescol in treating hypercholesterolemia in hypertension patients (an analysis of the data from a multicenter study)].
D. Aronov (1995)
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes
Kazunori Yanagi (2011)
Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
K. H. Yun (2012)
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
H. Bays (2011)
Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
C. Arampatzis (2005)
Efficacy of alternate day versus daily dosing of rosuvastatin.
D. Dulay (2009)
Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome
R. Rosenson (2009)
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia.
J. Rindone (1998)
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance
O. Celik (2012)
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
A. Yamamoto (2002)
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
P. Couvert (2008)
The effect of fluvastatin (Lescol) treatment on the clinical status and function of the liver in patients with ischemic heart disease
Kuril'skaia Te (1997)
スタチン新規処方の高コレステロール血症患者に対するストロングスタチン 3 剤の有効性の検討
順久 立石 (2011)
Efficacy and Safety of Fluvastatin-Extended Release in Hypercholesterolemic Patients: Morning Administration Is Equivalent to Evening Administration
H. Scharnagl (2006)
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
T. Andrews (2001)
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
M. Davidson (2003)
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
M. Lunder (2012)
Efficiency of 1-Year Treatment with Fluvastatin in Hyperlipidemic Patients with Nephrotic Syndrome
F. Matzkies (1999)
Heart disease and stroke statistics--2011 update: a report from the American Heart Association.
V. Roger (2011)
Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study.
Y. Homma (2003)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
M. Law (2003)
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin
L. Salek (2002)
Effects of Fluvastatin on Hyperlipidemia after Renal Transplantation: Influence of Steroid Therapy
J. Austen (1996)
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
B. Asztalos (2007)
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
I. Kanazawa (2009)
A systematic review and economic evaluation of statins for the prevention of coronary events.
S. Ward (2007)
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Balraj S Heran (2008)
Lipid-Lowering Effects of Fluvastatin in Renal Transplant Patients. A Clinical Observation
S. M. Lal (1997)
The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
A. Messerli (2003)
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial
K. Chan (2010)
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
W. Insull (2007)
Efficacy and Safety of Fluvastatin in Women with Primary Hypercholesterolemia
T. Peters (2012)
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
C. Ballantyne (2003)
Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir
A. Benesic (2004)
Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
T. Teramoto (1995)
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
P. Scuffham (2005)
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial.
K. Chan (2007)
A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.
E. Lesaffre (2003)
Lipid levels after acute coronary syndromes.
B. Pitt (2008)
Fluvastatin (lescol) treatment of hyperlipidaemia in patients with renal transplants
L. Löcsey (2006)
A COMPARISON OF CLINICAL AND PHARMACOECONOMIC PROPERTIES OF FLUVASTATIN AND SIMVASTATIN IN THE MANAGEMENT OF PRIMARY HYPERCHOLESTEROLAEMIA
L. Levin (1997)
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
J. Sasaki (1995)
Effect of Conventional and More Aggressive Rosuvastatin Treatment on Markers of Endothelial Activation
A. Postadzhiyan (2008)
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
J. Thompson (2005)
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
P. Lemos (2005)
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
L. Puccetti (2001)
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
Thomas M. van Himbergen (2009)
Skin blood flowmotion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases.
M. Rossi (2009)
Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives.
S. Anderssen (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
D. Murdock (1999)
高コレステロール血症患者に対するロスバスタチン 2.5 mg とアトルバスタチン 10 mg の脂質改善効果の比較
悟 角田 (2011)
Rosuvastatin Does Not Affect Fasting Glucose, Insulin Resistance, or Adiponectin in Patients with Mild to Moderate Hypertension
W. Kim (2013)
Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease.
H. Eichstaedt (2000)
Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
H. Holdaas (1995)
Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
D. Betteridge (1994)
Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
R. Goldberg (1996)
Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
M. Pirro (2007)
Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index
M. Porsch-Özcürümez (2014)
Safety and Efficacy of Fluvastatin in Hyperlipidemic Patients With Chronic Renal Disease
G. Yasuda (2004)
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
J. Mckenney (2007)
Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
K. Winkler (2002)
Comparative Cost-Effectiveness of Fluvastatin and Lovastatin in Patients with Hypercholesterolemia
D. Hilleman (2015)
Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands.
S. Chaplin (2004)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
H. Holdaas (2003)
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico
Germán Gómez Briseño (2010)
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
L. Spieker (2000)
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
S. Otokozawa (2009)
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.
Y. Saitō (2007)
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
C. Lamendola (2005)
Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study.
D. Jassal (2008)
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
B. Wolffenbuttel (2005)
Cellular Telephones and Interference With Privacy–Reply–III
D. Hayes (2007)
Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
G. Sigurdsson (1998)
ATORVASTATIN VS ROSUVASTATIN; FENOFIBRATE AS AN ADD ON: AN EXPLORATORY STUDY
M. A. Khan (2014)
Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
R. Knopp (1994)
Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report.
R. Knopp (1994)
The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
T. Lin (2000)
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
B. Fellström (2004)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
P. Jones (2003)
[Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients].
A. Semenova (2007)
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients*
A. Catapano (2006)
Are HIV positive patients resistant to statin therapy?
K. Johns (2007)
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
C. Ballantyne (2004)
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
C. Ballantyne (2000)
Effects of fluvastatin slow-release (xl 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes
M. Bevilacqua (2005)
Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans.
J. Yuan (1991)
Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients.
E. Bruckert (2003)
The Lescol ® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease
P. Serruys (2001)
Rosuvastatin Increases α‐1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia
M. Kostapanos (2006)
Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
D. Nash (1996)
Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
J. Edwards (2003)
The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients
A. Semenova (2009)
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.
G. Huhle (1999)
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
M. Davidson (2008)
Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.
Y. C. Schrama (1998)
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
R. Paoletti (2001)
PJ-835 The evaluation of myocardial injury in patients with acute myocardial infarction using 64-slice multi-detector computed tomography(CT / DSA(11)(I),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
K. Kongoji (2008)
Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population.
P. Coen (2010)
The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure.
C. Gürgün (2008)
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
I. Deguchi (2014)
[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
R. Češka (1996)
Time‐dependent effect of statins on platelet function in hypercholesterolaemia
L. Puccetti (2002)
Association of Bicuspid Aortic Valve Morphology and Aortic Root Dimensions: A Substudy of the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin (ASTRONOMER) Study
D. Jassal (2010)
Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
G. Fanghänel (1995)
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
H. Bays (2008)
Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial.
R. Capoulade (2014)
Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study.
M. Lunder (2011)
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
M. Bertolotti (2012)
Efficacy and Safety of Rosuvastatin Every Other Day Compared with Once Daily in Patients with Hypercholesterolemia
S. Wongwiwatthananukit (2006)
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
B. Okopień (2004)
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
P. Deedwania (2007)
Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction
S. Westphal (2009)
Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial
A. R. Arshad (2014)
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
C. Ballantyne (1999)
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins
P. Jones (2008)
Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers
J. Kiser (2008)
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
E. Stein (2008)
Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS)
C. Ballantyne (1998)
Lowering effects of four different statins on serum triglyceride level
A. Branchi (1999)
Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia.
B. Okopień (2004)
Lipid lowering efficacy of rosuvastatin
S. P. Adams (2014)
Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation.
F. Saia (2004)
Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background
D. Choumerianou (2005)
Ji Zhen-guo (2008)
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Polenova Nv (2009)
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
M. Davidson (2002)
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Debra L. Weinstein (2013)
LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study
J. Wouter Jukema (2005)
LDL‐receptor gene mutations and the hypocholesterolemic response to statin therapy
J. U. Brorholt-Petersen (2001)
Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin).
A. Pagé (2010)
Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia
J. Park (2010)
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
B. Pitt (2012)
Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
T. Inoue (2011)
Elderly patients with hypercholesterolaemia: a double‐blind study of the efficacy, safety and tolerability of fluvastatin
M. Lye (1998)
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
R. Cheung (2005)
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
K. Koh (2013)
Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.
F. Fonseca (2006)
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes
D. Betteridge (2007)
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
O. Hussein (1997)
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
D. Capuzzi (2003)
Use of fluvastatin following percutaneous coronary intervention
P. Scuffham (2005)
Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
P. Lemos (2005)
Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia
E. Leitersdorf (2004)
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
H. Z. Mirdamadi (2008)
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
A. Polis (2009)
Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency.
P. Alaupovic (2006)
Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy
S. Lutucuta (2001)
An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK
P. Scuffham (2012)
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
G. Schwartz (2004)
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
A. Bellia (2010)
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
A. Olsson (2002)
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
H. Avis (2010)
Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study.
T. Mcguire (2014)
Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).
A. Binbrek (2006)
Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
S. Hailer (1996)
Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia.
Hsin‐Bang Leu (2004)
Clinical implications of the biopharmaceutical properties of fluvastatin.
J. Deslypere (1994)
Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
J. Dallongeville (1994)
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia
Eli M. Roth (2010)
[Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients].
P. Wang (2014)
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
D. Betteridge (2007)
Right bundle branch block, persistent ST-segment elevation, and sudden death.
RuDusky Bm (1998)
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
M. W. Russell (2001)
The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia.
T. Šejda (2006)
Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.
Evan A. Stein (2007)
Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.
K. Winkler (2004)
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
P. Serruys (2002)
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
H. Yokoi (2014)
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Shinnya Miwa (2005)
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
R. Gao (2007)
[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
J. Widimský (1999)
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
Clinical usefulness of tissue Doppler imaging in patients with mild to moderate aortic stenosis: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study.
D. Jassal (2008)
Efficacy and Safety of Slow‐release Fluvastatin 80 mg Daily in Chinese Patients with Hypercholesterolemia
Chih-Cheng Wu (2005)
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
C. Ballantyne (2007)
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
J. M. Bard (1995)
Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial
D. Sheridan (2014)
Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.
H. Osamah (1997)
Relation between perfusion defects on stress technetium-99m sestamibi SPECT scintigraphy and the location of a subsequent acute myocardial infarction.
G. Miller (1996)
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia
T. Katabami (2014)
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
M. Kostapanos (2008)
A COMPARISON BETWEEN FLUVASTATIN AND LOVASTATIN EFFECTS IN IRANIAN PATIENTS WITH HYPERCHOLESTEROLEMIA
S. Moradm (1998)
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Nuntakorn Thongtang (2011)
Valsartan Therapy Has Additive Anti-oxidative Effect to That of Fluvastatin Therapy Against Low-Density Lipoprotein Oxidation: Studies in Hypercholesterolemic and Hypertensive Patients
O. Hussein (2002)
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
H. Domingos (2012)
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
R. Lloret (2006)
Effects of Fluvastatin Treatment on Insulin Sensitivity in Patients with Hyperlipidaemia
BY Cingözbay (2002)
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.
M. Florentin (2013)
Effects of Rosuvastatin and Colestimide on Metabolic Parameters and Urinary Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients with Hyperlipidemia
K. Takebayashi (2009)
Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women
J. Fernández (2001)
The Cost-Effectiveness of Fluvastatin in Hungary Following Successful Percutaneous Coronary Intervention
P. A. Scuffham (2006)
[Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease].
I. Sergienko (2006)
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
B. Asztalos (2002)
Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction.
M. Lorena (1997)
A FLUVASTATIN HATASA A SZERUM LIPID SZINTEKRE ESSZENCIALIS HIPERTONIAS BETEGEKBEN
Z. Járai (1996)
Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
J. Smit (1995)
Inhibition of intestinal cholesterol absorption might explain cholesterol‐lowering effect of telmisartan
T. Inoue (2011)
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
T. Lu (2004)
Effects of fluvastatin, an HMG‐CoA reductase inhibitor, on serum levels of interleukin‐18 and matrix metalloproteinase‐9 in patients with hypercholesterolemia
Hsin‐Bang Leu (2005)
Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia
Zhao Rui-ping (2013)
The MERCURY II trial: benefits of rosuvastatin
L. Izzat (2006)
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study.
K. Sing (1999)
Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.
P. Coen (2009)
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals
W. Leonhardt (1997)
A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients
Juan-Osvaldo Talavera (2013)
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
C. Ballantyne (2013)
Gender-Related Response to Fluvastatin in Patients with Heterozygous Familial Hypercholesterolaemia
E. Leitersdorf (2012)
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
W. Brown (2002)
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
J. Herd (1997)
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment
E. Coban (2008)
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
L. Álvarez-Sala (2008)
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
J. Mckenney (2003)
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia
M. Davidson (2014)
A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
R. Goldberg (1995)
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
E. Leitersdorf (1995)
Management of hyperlipidaemia. Why, when and how to treat.
M. Oliver (1997)
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.
M. Gliozzi (2013)
Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease
F. Khan (1999)
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
E. Stein (2003)
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
E. Stein (2007)
Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia.
Kohei Fujimoto (2004)
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
P. Jones (2004)
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*
J. Shepherd (2004)
Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery
G. Kouvelos (2013)
The MERCURY I open-label extension study — subgroup analysis in patients with diabetes:
H. Schuster (2008)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
P. Durrington (2004)
Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein.
P. L. van Haelst (2001)
Chapter 8: Assessing risk of bias in included studies
J. P. Higgins (2008)
Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
H. Mori (2013)
The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters
Filippova Vg (1997)
Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
L. Calza (2013)
Effects of 1-year treatment with fluvastatin or pravastatin on bone.
S. Watanabe (2001)
Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia.
H. Avis (2011)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
J. Pincus (1998)
Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
M. Smith (2009)
Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention
J. Kowalski (2006)
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
B. Jacotot (1995)
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol
S. Bergheanu (2007)
Safety and tolerability of fluvastatin XL in the treatment of hyper-cholesterolemia : a postmarketing surveillance conducted in Indonesia
A. Setiawati (2008)
Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy.
R. Capoulade (2012)
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
R. Nohara (2012)
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
M. Milani (1996)
Effects of Rosuvastatin and Atorvastatin on Low-Density and High-Density Lipoprotein Particle Concentrations in Patients With Metabolic Syndrome: A Randomized, Double-Blind, Controlled Study
R. Rosenson (2009)
STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D.
D. Ertuğrul (2011)
Predictive Value of the Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence in Japanese Patients Treated with Rosuvastatin
M. Igase (2012)
Evaluation of plaque stabilization by fluvastatin with carotid intima- medial elasticity measured by a transcutaneous ultrasonic-based tissue characterization system.
T. Yamagishi (2009)
Effect of Fluvastatin in Combination with Moderate Endurance Training on Parameters of Lipid Metabolism
R. Wittke (1999)
Imputing missing standard deviations in meta-analyses can provide accurate results.
T. Furukawa (2006)
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
C. Ballantyne (2006)
Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
P. Anagnostis (2014)
Fluvastatin improves insulin resistance in nondiabetic dyslpidemic patients
A. Sonmez (2007)
Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function
M. Pirro (2009)
Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
M. Moghadasian (1999)
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
A. Marian (2000)
[Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease].
L. Szapáry (2012)
Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
B. Tomlinson (1995)
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
W. Insull (1994)
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy.
T. Jacobson (1994)
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
J. Herd (1994)
Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
R. Nohara (2013)
Fluvastatin Treatment and Withdrawal: Effects on Endothelial Function
S. Westphal (2008)
Fluvastatin in the treatment of hypercholesterolemia in renal transplantation.
G. Gómez (1999)
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study.
S. Chen (2004)
Treatment with Fluvastatin Rapidly Modulates, via Different Pathways, and in Dependence on the Baseline Level, Inflammation in Hemodialysis Patients
G. Tsirpanlis (2004)
Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia
Anouk van der Graaf (2006)
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
Michael S West (1996)
Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia
D. Hunninghake (2002)
Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X
Xinling Zhang (2014)
Effects of Alcohol and Fluvastatin on Lipid Metabolism and Hepatic Function
J. Smit (1995)
Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism
A. Her (2010)
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
S. Grundy (1993)
Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection.
P. Chong (2005)
Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
I. Seres (2005)
Treatment of metabolic disorders with fluvastatin after renal transplantation.
H. Podder (1997)
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin*
F. Fonseca (2005)
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
D. Hunninghake (1998)
Dyslipidemic drugs in metabolic syndrome
S. S. Siddiqi (2013)
A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin
D. D. Illingworth (1996)
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
M. Romano (2000)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
P. Jones (1998)
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
C. Ballantyne (2001)
Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia
M. Davidson (2001)
Fluvastatin with and without niacin for hypercholesterolemia.
T. Jacobson (1994)
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study
S. Simsek (2012)
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
J. M. Izquierdo-Palomares (2016)
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis.
K. Chan (2011)
Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin
N. A. J. van der Linde (2006)
Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors
L. Calza (2012)
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
D. Tousoulis (2011)
[Effect of statin therapy on dynamics of vascular endothelial growth factor and fibroblast growth factor in patients with ischemic heart disease].
I. Sergienko (2007)
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
O. Samuelsson (2002)
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
E. Mills (2008)
Rosuvastatin effect on intima media thickness in adult vs elderly patients.
G. Riccioni (2012)
Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
P. Ambrosi (2000)
Plasma lipids and blood fluidity in patients with polygenic hypercholesterolaemia treated with fluvastatin.
F. Piñón (2002)
Fluvastatin Titrate‐to‐Goal Clinical Practice Study
R. Weiss (1998)
Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
J. Isaacsohn (2003)
[Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study].
G. Abetel (1998)
FOCUS ON ATORVASTATIN : AN HMG-COA REDUCTASE INHIBITOR FOR LOWERING BOTH ELEVATED LDL CHOLESTEROL AND TRIGLYCERIDES IN HYPERCHOLESTEROLEMIC PATIENTS
K. Kellick (1997)
Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus
F. Visseren (2001)
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance
E. Moutzouri (2011)
Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia: Possible Improvement of Intraplatelet Redox Imbalance via HMG-CoA Reductase
N. Haramaki (2007)
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
P. Li (1995)
Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemia
F. E. Broyles (1995)
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
E. Hagen (2004)
Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
J. E. Burmeister (2009)
Comparison of the Lipid-Lowering Effects of Fluvastatin, Lovastatin and Simvastatin in Patients with Hyperlipoproteinaemia
G. Paragh (1999)
The effect of fluvastatin of hyperlipidemia in renal transplant recipients: A prospective, placebo- controlled study
S. Türk (2004)
Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
T. Akiyama (2001)
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
A. Blann (2001)
Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia
O. Faergeman (2008)
[EFFECT OF ASCORBIC ACID ON THE DISTRIBUTION OF 4-C-14-CHOLESTEROL IN TISSUES IN EXPERIMENTAL ATHEROSCLEROSIS].
Zaĭtsev Vf (1964)
[Factors associated with low ankle-brachial index in patients with type 2 diabetes and prediabetes].
Polenova Nv (2009)
Saudi Arabia experience trial of fluvastatin (Lescol) in the treatment of hyperlipidemia.
Galal Ms (1997)
Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype
W. Maerz (2001)
Rosuvastatin Reduces Plasma Small Dense LDL-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients
G. Yoshino (2012)
Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia
M. Kostapanos (2009)
Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
Y. Saitō (2003)
Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia
M. Igase (2012)
Apolipoproteins: the new prognostic indicator?
C. Packard (2003)
Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function.
B. Takase (2014)
High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
A. Agouridis (2011)
Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study
B. Wolffenbuttel (2005)
Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
S. Sasaki (1997)
Effects of fluvastatin on humanbiliary lipids
S. Tazuma (1995)
Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
B. Jacotot (1994)
Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)
C. H. Lee (2004)
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters
I. Karalis (2010)
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
M. Clearfield (2006)
Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
H. Daida (2014)
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
P. Jones (2009)
More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
Ida Robertsen (2014)
Pleiotropic effects of statins.
J. Liao (2005)
Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
D. Eisenberg (1998)
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
M. Gadarla (2008)
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease.
M. van Dam (2001)
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
C. Ballantyne (2008)
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
E. Schaefer (2004)
Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects
F. Bruni (2003)
The impact of social determinants on cardiovascular disease.
C. Kreatsoulas (2010)
Comparision of Effects of Rosuvastatin Versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients With Hyperlipidemia Having Coronary Artery Disease
E. Kurtoğlu (2014)
Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients
D. Sprecher (1994)
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
M. Costa-Scharplatz (2008)
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
K. Ferdinand (2006)
Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates
B. Okopień (2005)
Effects of short-term rosuvastatin therapy on heart and kidney function in patients with acute coronary syndrome combining diabetes mellitus and concomitant chronic kidney disease
Heng Wu (2014)
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
L. Calza (2008)
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events
T. Stojaković (2010)
A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects.
C. Eagles (1996)
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
C. Lintott (1995)
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
C. Dujovne (1994)
Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
R. Rosenson (2010)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
S. Boekholdt (2012)
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
E. Moutzouri (2013)
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
J. Zhu (2007)
Primary PTCA versus thrombolytic therapy for acute MI
Tayo A Addo (2003)
Efficacy and Safety of Rosuvastatin in Taiwanese Patients
C. Chiang (2008)
Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.
E. Haak (2001)
Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
A. Olsson (2001)
Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
M. Bevilacqua (2004)
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Manon J van der Lee (2007)
A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia.
B. Zhang (2005)
The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia
A. Sonmez (2006)
Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study.
D. Hilleman (2000)
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
A. Olsson (2001)
Efficacy and safety of rosuvastatin and atorvastatin in aged patients with hypercholesterolemia
Wang Yu-hong (2008)
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
A. Goldberg (2011)
Efficacy of rosuvastatin in the treatment of early diabetic nephropathy
Liu Zhi-hua (2012)
Fluvastatin increases bone mineral density in postmenopausal women.
Mituhiro Gotoh (2011)
Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity
A. Tambaki (2004)
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
P. Miller (2005)
Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention.
J. Smit (1999)
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment
Franca Marino (2012)
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
P. Deedwania (2005)
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial
S. Stender (2005)
Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C
K. Patel (2011)
Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
M. Milani (1995)
Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
J. Koizumi (1995)
Efficacy and safety of fluvastatin in elderly hypercholesterolemic patients : a pilot study
G. Baggio (1994)
This paper is referenced by
Pathophysiology and treatment of atherosclerosis
S. Bergheanu (2017)
Potential and Limitations of Cochrane Reviews in Pediatric Cardiology: A Systematic Analysis
Martin Poryo (2017)
Metabolic Alterations in Cardiopulmonary Vascular Dysfunction
Valérie Françoise Smolders (2019)
Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy
Justin Morrison (2016)
Cerivastatin for lowering lipids.
Stephen P. Adams (2017)
Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care
Furio Colivicchi (2016)
Atorvastatin for lowering lipids
S. Adams (2015)
فلوواستاتین برای کاهش چربیهای خون
S. Adams (2018)
Comparison of lifestyle changes and pharmacological treatment on cardiovascular risk factors
P. Marques-Vidal (2020)
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
Veronica Azemawah (2019)
Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance.
Haris Riaz (2017)
Review on Rosuvastatin
Sri Ch (2016)
Pitavastatin for lowering lipids
S. P. Adams (2017)
Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study.
B. Nussbaumer-Streit (2018)